News | August 02, 2011

Study Shows Cigarette Smoking Increases Risk of Developing Atrial Fibrillation

August 2, 2011 — Results from a large, United States-based cohort study show that current smokers double their risk of developing atrial fibrillation (AF) compared to people who have never smoked, after more than 13 years of follow-up. The study, published in the August edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), indicates a trend towards significantly lower risk of developing AF for those who quit smoking cigarettes versus those who continue to smoke.

According to the HRS, AF is a very common heart rhythm disorder with more than 2 million people in the United States diagnosed and about 160,000 new cases identified each year. While several risk factors have been identified, including obesity, hypertension and diabetes, the association between smoking and AF is less clear.

Between 1987 and 1989, the Atherosclerosis Risk in Communities (ARIC) study enrolled a population-based cohort of over 15,000 black and white participants aged 45-64 years. All participants were questioned at baseline about the number of cigarettes smoked per day, smoking status (current, former or never) and age at smoking initiation or cessation.

Study analysis conducted by Alanna Chamberlain, Ph.D., and co-authors reports 876 incident AF events during an average 13-year follow-up period. The risk of AF was found to be 1.32 times greater among former smokers and twofold higher in current smokers than in nonsmokers. In addition, compared to nonsmokers, former heavy smokers had an 89 percent increased risk of developing AF, while current heavy smokers had a 131 percent increased risk, indicating that quitting smoking lowers the risk of developing AF.  Specifically, there was a 12 percent lower risk of AF among individuals who quit smoking versus individuals who continued smoking.

“AF is a serious health issue that decreases quality of life and significantly increases the risk of stroke,” stated co-author Alanna M. Chamberlain, Ph.D, MPH, department of health sciences research at the Mayo Clinic in Rochester, Minn. “It is my hope that our study findings will shed more light on the impact that smoking has on cardiovascular diseases, and help individuals realize they can play a role in preventing the development of atrial fibrillation.”

These results support previous findings that smoking increases the risk of AF development. The findings also show that associations between smoking and AF do not differ between blacks and whites, despite overall incident rates being lower in blacks. Furthermore, this is the first study to document differences in AF development between participants who remained smokers throughout the study follow-up and those who stopped smoking. Future studies may choose to focus on the role of smoking cessation in the prevention of AF development.

For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init